Options for Third- and Further-Line Treatment of HER2+ mBC

Dr Debu Tripathy explains the treatment options for patients with HER2+ metastatic breast cancer in the third-line and later-line settings, including combination tucatinib/trastuzumab/capecitabine.

Related Videos
Lisa A. Carey MD, ScM, FASCO
Expert on urothelial carcinoma
Experts on urothelial carcinoma
Susan Domchek, MD, FASCO
Expert on CSCC
Expert on CSCC
Experts on BTC
Experts on BTC
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Expert on AML
Related Content